Key points are not available for this paper at this time.
The bispecific antibodies (bsAbs) teclistamab and talquetamab have received United States Food and Drug Administration (FDA) approval for use in relapsed/refractory multiple myeloma (MM) following remarkable single-agent activity in early-phase clinical trials 1 , 2 , 3 .The FDA-approved treatment schedule for teclistamab involves initial step-up dosing (SUD) followed by 1.5 mg per kilogram (mg/kg) dosed once per week (Q1W) with the option of 1.5 mg/kg dosing every two weeks (Q2W) in patients who have maintained a complete response (CR) for at least 6 months. The FDA-approved treatment schedule for talquetamab consists of either 0.4 mg/kg Q1W or 0.8 mg/kg Q2W dosed until progression.
Chunara et al. (Tue,) studied this question.